semaglutide e European Commission Approves 7.2 mg Once-Weekly Wegovy Dose for Adults With Obesity Semaglutide as a MASH Treatment:

Unfortunately, although a medication is used to fix one problem in your body, it often causes unpleasant side effects

The FDA approved an oral semaglutide tablet for weight loss in December 2025

Emerging studies suggest possible benefits in glaucoma, ocular surface disease, and some retinal vascular outcomes, while evidence for age-related macular degeneration and cataract remains limited or conflicting

I know that many patients and families who live with rare genetic diseases of obesity face an often-burdensome stigma associated with severe obesity at any age

These effects are typically most pronounced during dose escalation and often diminish with continued use, though some patients experience persistent symptoms requiring dose adjustment or discontinuation

GSH forms S-nitrosoglutathione (GSNO) , which serves as a stable NO carrier and reservoir in the body